TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $386,047 | -41.8% | 43,182 | 0.0% | 0.00% | – |
| Q2 2023 | $663,275 | -31.7% | 43,182 | 0.0% | 0.00% | -100.0% |
| Q1 2023 | $971,163 | +78346.1% | 43,182 | -26.7% | 0.00% | 0.0% |
| Q4 2022 | $1,238 | -99.9% | 58,873 | -11.3% | 0.00% | 0.0% |
| Q3 2022 | $1,635,000 | +1.7% | 66,362 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,608,000 | -6.1% | 66,362 | -0.1% | 0.00% | 0.0% |
| Q1 2022 | $1,712,000 | +25.1% | 66,445 | +50.6% | 0.00% | 0.0% |
| Q4 2021 | $1,369,000 | +100.4% | 44,118 | +56.6% | 0.00% | – |
| Q3 2021 | $683,000 | +112.1% | 28,180 | +27.7% | 0.00% | – |
| Q2 2021 | $322,000 | -41.6% | 22,070 | 0.0% | 0.00% | – |
| Q1 2021 | $551,000 | -8.5% | 22,070 | 0.0% | 0.00% | – |
| Q4 2020 | $602,000 | – | 22,070 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |